Document:

Exhibit 10.3

 

Free English translation – for information
purposes

 

 

Free Translation

 

This English version of the May 2014 Stock Option
Plan of MDxHealth SA is a free translation of the original French version. In case of discrepancies between the original French version
and this English version, the original French version shall prevail.

 

MAY 2014 STOCK OPTION PLAN

 

MDxHealth SA

 

    1/9

     

    

 

Free English translation — for information
purposes

 

Article
1 - PURPOSE OF THE PLAN

 

This May 2014 Stock Option Plan (the “Plan”)
describes the general conditions of the Stock Options that the Company issued to the Selected Participants.

 

The aim of the Plan is to realize the following corporate
and human resources goals:

 

		(i)	to encourage and motivate the Selected Participants;

 

		(ii)	to enable the Company and its Subsidiaries to attract and retain directors, employees and consultants
with the required experience and skills;

 

		(iii)	to link the interests of the Selected Participants closer to the interests of the shareholders of the
Company by giving them the opportunity to share in the increase of the value of the Company.

 

Article
2 -DEFINITIONS AND INTERPRETATION

 

The following terms shall have the following meaning
for the purpose of the Plan:

 

	Beneficiary	 	With respect to a natural person, a person validly designated by the Selected Participant, being either his/her spouse or legal heirs, in order to exercise the rights of the Selected Participant under the Plan after the death of the Selected Participant. Designation, revocation and re-designation of a Beneficiary must be done in writing in accordance with the applicable law. In the absence of any valid designation, the heirs of the Selected Participant in accordance with the applicable law of inheritance shall be deemed to be the Beneficiary. In the event that there are several heirs, all heirs acting jointly or one person designated by all heirs acting jointly shall be deemed to be the Beneficiary;
	 	 	 
	Board of Directors	 	The board of directors of the Company;
	 	 	 
	Company	 	MDxHealth SA, a company established under Belgian law, having its registered office at Rue d’Abhooz 31 - Cap Business Center, 4040 Herstal, Belgium, registered with the register of legal persons under number 0479.292.440;
	 	 	 
	Consultant	 	Any person or legal entity that is not an employee of the Company or a Subsidiary and that is performing services for the Company or a Subsidiary;
	 	 	 
	Control	 	The possibility de facto or de jure to exercise a decisive influence over the appointment of the majority of the members of the Board of Directors or the general orientation of the Company, as determined in Article 5 and following of the Belgian Company Code;
	 	 	 
	Date of Grant	 	The date on which the offer of the Stock Options to a Selected Participant is made;
	 	 	 
	Date of Issuance	 	The date on which the Stock Options will be issued, i.e. May 30, 2014; or in case of absence of the required quorum at such meeting, June 23, 2014;
	 	 	 
	Date of Termination of the director’s mandate, the employment or consultancy agreement	 	The effective date of termination of the director’s mandate, the employment agreement, or as applicable, the consultancy agreement for whatever reason, with the exception of a termination of a consultancy agreement immediately followed by the signing of an employment or a new consultancy agreement with the Company or a Subsidiary, a termination of an employment agreement immediately followed by the signing of a new employment or consultancy agreement with the Company or a Subsidiary, and the termination of a director’s mandate immediately followed by the reappointment of such director as Director the Company or a Subsidiary;
	 	 	 
	Director	 	A member of the board of directors of the Company or a Subsidiary;
	 	 	 
	Employee	 	An individual having an employment agreement of an indefinite term with the Company or a Subsidiary;

 

    2/9

     

    

 

Free English translation — for information
purposes

 

	Executive	 	Any person responsible for the general management of the Company within the meaning of Article 96, §3, 11° of the Belgian Company Code;
	 	 	 
	Exercise Period	 	The period during which the Selected Participant can exercise the Stock Options granted to him/her, provided and to the extent that the Stock Options are exercisable in accordance with the conditions set forth in the Plan and in any other arrangement that may exist between the Selected Participant and the Company;
	 	 	 
	Exercise Price	 	The price at which each Share subject to a Stock Option may be acquired/subscribed to upon the exercise of that Stock Option;
	 	 	 
	Extraordinary General Shareholders Meeting	 	The extraordinary general shareholders’ meeting held before a notary public at the occasion of which the Stock Options are issued by the Company;
	 	 	 
	Notification	 	A letter sent to the official domicile or registered office of the addressee by means of (i) a courier with notice of receipt or (ii) a registered letter. The date of the Notification is: (i) the date of signing for receipt or, in the absence thereof, (ii) the postmarked date of the registered letter;
	 	 	 
	Plan	 	The present May 2014 Stock Option Plan;
	 	 	 
	Selected Consultant(s)	 	Consultant(s) selected to accept Stock Options under this Plan;
	 	 	 
	Selected Director(s)	 	Director(s) selected to accept Stock Options under this Plan;
	 	 	 
	Selected Employee(s)	 	Employee(s) selected to accept Stock Options under this Plan;
	 	 	 
	Selected Participant(s)	 	The Selected Directors, the Selected Employees and/or Selected Consultants to take up Stock Options under this Plan, it being understood that the Stock Options issued under this Plan shall mainly be offered to Selected Employees;
	 	 	 
	Shares	 	The shares of the Company having the same rights and advantages as the existing ordinary shares of the Company;
	 	 	 
	Stock Option	 	A warrant issued by the Company entitling the Selected Participant to acquire/subscribe to a Share pursuant to the Plan during a certain period at a certain price;
	 	 	 
	Stock Option Price	 	The price, if any, which the Selected Participant owes to the Company for the acquisition of the Stock Option itself;
	 	 	 
	Subsidiary	 	Any company or organization which is directly or indirectly under the Control of the Company;
	 	 	 
	Take-Over	 	The official notification by the FSMA of a take-over bid within the meaning of Article 3 § 1, 1° of the Act of April 1st, 2007 on takeover bids (or within the meaning of any other subsequent legislation replacing, amending or completing the foregoing);
	 	 	 
	Transfer – Transferring	 	Any transaction under living persons which has as its purpose the sale, purchase, granting or taking of options, exchange, waiver, contribution to a company, transfer in any manner whether or not for consideration, the giving of payment or pledge, or the acceptance of payment or pledge, or generally any agreement which has as its object an immediate or future transfer of title;
	 	 	 
	Vested Stock Options	 	Stock Options that have become definitely acquired by the Selected Participant in accordance with the conditions set forth in the Plan, without prejudice to the possibility that the Stock Options become void in cases where they are not exercised or can no longer be exercised pursuant to certain conditions.

 

    3/9

     

    

 

Free English translation — for information
purposes

 

Except insofar as the context otherwise requires,
(i) words denoting the singular shall include the plural and vice versa and (ii) words denoting the masculine gender shall include the
feminine gender and vice versa.

 

Article
3 -TYPE AND NUMBER OF STOCK OPTIONS

 

		3.1	The total number of Stock Options issued under the Plan is 1,500,000
(one million five hundred thousand).

 

		3.2	Each Stock Option shall entitle a Selected Participant to acquire one
(1) Share.

 

The new Shares issued at the occasion
of the exercise of the Stock Options shall have the same rights and benefits as, and rank pari passu in all respects with, the existing
and outstanding Shares of the Company at the time of their issuance, and will be entitled to distributions in respect of which the relevant
record date or due date falls on or after the date of issue of the Shares.

 

A new Share shall represent the same
fraction of the capital of the Company as the other outstanding Shares of the Company.

 

Article
4 -ADMINISTRATION

 

The Board of Directors shall administer the Plan.
The Board of Directors shall have the possibility to delegate its powers or certain of its powers to certain persons of the management
and/or to certain committees that may be established by the Board of Directors, in compliance with the Belgian Company Code and the Company’s
Charter of Corporate Governance.

 

Subject to the provisions of the Plan and in as far
as the decisions are in line with the purpose of the Plan, the Board of Directors is entitled to determine, define and interpret all rules,
regulations or other measures required or desirable for the administration of the Plan.

 

Article
5 -CONDITIONS OF THE STOCK OPTIONS

 

		5.1	Stock Option Price

 

Except where the Board of Director decides
otherwise, on a one to one basis, the Selected Participant shall owe no Stock Option Price to the Company upon subscription to, or acceptance
of, the Stock Options.

 

		5.2	Exercise Price

 

The Exercice Price of a Stock Option
shall be determined by the Board of Directors of the Company on the Date of the Grant thereof. For each Selected Participant, the Exercise
Price shall never be less than the fractional value of the Shares. For each Selected Participant who is not a Selected Employee, the Exercise
Price shall not be lower than the higher of (i) the average price of the Shares on Euronext Brussels during the period of 30 days preceding
the Date of Issuance and (ii) the average price of the Shares on Euronext Brussels during the period of 30 days preceding the Date of
Grant of the Stock Options. For each Selected Participant who is a Selected Employee, the Exercise Price shall not be lower than the lower
of (i) the price of the Shares on Euronext Brussels on the day prior to the Date of Grant and (ii) the average price of the Shares on
Euronext Brussels during the period of 30 days preceding the Date of Grant.

 

Upon exercise of a Stock Option, the
Exercise Price must be booked as capital up to an amount equal to the fractional value of the existing shares of the Company. The remainder
must be booked as an issuance premium, that shall represent, to the same extent as the capital, a guarantee for third parties, and shall
be booked on an unavailable account that can only be decreased or booked away by a decision of the general shareholders’ meeting
deciding in the same way as for a modification of the bylaws.

 

		5.3	Term (duration) of the Stock Options

 

The duration of a Stock Option shall
be ten (10) years as of their Date of Issuance. However, the Board of Directors shall have the right to shorten this term.

 

    4/9

     

    

 

Free English translation — for information
purposes

 

		5.4	Registered nature

 

The Stock Options are and shall remain
registered, and shall be entered in the register of warrant holders that shall be held at the registered office of the Company. The Stock
Options may not be converted into bearer Stock Options. The Company shall deliver to each Selected Participant and Beneficiary, free of
charge, a certificate confirming that he/she is duly registered in the register of warrant holders as owner of the Stock Options held
by him/her.

 

		5.5	Rights as a shareholder

 

The Selected Participant (in his/her
capacity as holder of a Stock Option) is not a shareholder of the Company, nor shall he/she have any rights or privileges, which as a
rule belong to a shareholder of the Company, as long as the Stock Options have not been exercised.

 

Article
6 -TRANSFER OF THE STOCK OPTIONS

 

		6.1	Decease

 

In case the holder of a Stock Option
is a natural person, the following will apply: in the event of the decease of a Selected Participant, all Stock Options (including the
Vested Stock Options at the time of decease) shall be transferred to the Beneficiary of the Selected Participant and shall be (or remain
as far as the Vested Stock Options are concerned) exercisable at the time and under the terms established in this Plan.

 

	6.2	Transferability of the Stock Options

 

Except for the transfer contemplated
under Article 6.1 above and except if the Board of Directors were to allow a transfer of the Stock Options, the Stock Options cannot be
Transferred by a Selected Participant once they have been granted to a Selected Participant.

 

Article
7 -EXERCISE OF THE STOCK OPTIONS

 

Stock Options can only be exercised during an Exercise
Period (as specified in Article 7.2 below) provided and to the extent that they have become Vested Stock Options and have become exercisable
(in accordance with Article 7.1 below) prior to or during a certain Exercise Period.

 

		7.1	Vesting and exercisability of the Stock Options

 

The vesting schedule of a Stock Option,
i.e. the dates and conditions upon which it shall become a Vested Stock Option, shall be as set forth in this Plan, except where, for
Stock Options granted to Selected Participants in any capacity other than the capacity of Selected Directors, the Board of Directors determines
otherwise and, for Stock Options granted to Selected Participants in their capacity of Selected Directors, the general shareholders’
meeting determines otherwise.

 

		7.1.1	General vesting mechanism of the Stock Options

 

Unless otherwise determined by the Board
of Directors, the Stock Options subscribed to by a Selected Participant in any capacity other than the capacity of Selected Director shall
vest, i.e. become Vested Stock Options, in installments of twenty-five percent (25%) per year during a period of four (4) years as of
the Date of Grant, as follows:

 

		●	during the second year from the Date of Grant: maximum 25%, i.e. maximum 50% in total over the first two
years after the Date of Grant;

 

		●	during the third year from the Date of Grant: maximum 25%, i.e. maximum 75% in total over the first three
years after the Date of Grant;

 

		●	as from the fourth year from the Date of Grant: 25%, i.e. maximum 100% in total over the first four years
after the Date of Grant.

 

    5/9

     

    

 

Free English translation — for information
purposes

 

During the second, the third, and the
fourth years after the date of Grant, the Stock Options subscribed to by a Selected Participant in any capacity other than that of non-Executive
Selected Director shall vest on a quarterly basis, i.e. for an amount that bears the same proportion to the maximum amount of Stock Options
that can vest during that period as the number of (full) quarters that have passed during said given period bears to the total number
of quarters of that period. For example, one year and seven months after the Date of Grant, a maximum of 37.5% of the Stock Options granted
to a Selected Participant could be Vested Stock Options.

 

Except where the general shareholders’
meeting decides otherwise, at each of the annual shareholders’ meeting of respectively 2015 and 2016, 10,000 Stock Options will be offered
to each person or entity who will be a non-Executive Director of the Company on the date of such meeting. At the annual shareholders’
meeting of 2014, an additionnal (i.e. on top of the stock options offered on the basis of the May 2012 Stock Option Plan) 4,000 Stock
Options will be offered to each person or entity who will be a non-Executive Director of the Company on the date of such meeting. The
Stock Options granted to a non-Executive Director shall all vest, i.e. become Vested Stock Options, on the date of the annual shareholders’
meeting that takes place in the calendar year following the calendar year where the Stock Options were granted, provided that on the date
preceding the date of the former annual shareholders’ meeting the mandate of such non-Executive Director has not terminated (without
prejudice to section 7.1.3 of the Plan).

 

Notwithstanding the foregoing, all Stock
Options subscribed for by a Selected Participant shall automatically vest (if not yet vested) and become Vested Stock Options in the event
of a Take-Over.

 

		7.1.2	Exercisability of the Stock Options

 

The Selected Participants are allowed
to exercise any Vested Stock Options during any Exercise Period as of and from, (i) with respect to Selected Participants qualifying as
Executives or Directors, the third anniversary of the Date of Grant (the start of the fourth year) and (ii) with respect to Selected Participants
not qualifying as Executives or Directors, the moment where such Stock Options became Vested Stock Options. The rules set forth in section
7.1.3. below however prevail over the rules set forth in this section 7.1.2.

 

		7.1.3	Consequences of termination of a director’s mandate, an employment agreement or a consultancy agreement

 

Without prejudice to the provisions
of the following paragraphs and unless otherwise determined by the Board of Directors or the Chief Executive Officer (Managing Director)
of the Company, when (i) with respect to Directors, the director’s mandate of a Selected Director is terminated for other reasons
than for breach of his duties as a Director, (ii) with respect to Employees, the employment agreement of a Selected Employee is terminated
for other reason than for serious cause, or (iii) with respect to Consultants, the consultancy agreement of the Selected Consultant is
terminated for other reasons than breach of said agreement, in each such case the Selected Participant may exercise all his Stock Options
that have become Vested Stock Options at the Date of Termination of the director’s mandate, the employment agreement or, as applicable,
the consultancy agreement, at the times and in accordance with the conditions set forth in the Plan, (i) with respect to Selected Participants
qualifying as Executives or Directors, within a period starting as set forth in section 7.1.2. and expiring on the later of (a) the fourth
anniversary of the Date of Grant and (b) one year as from the Date of Termination of the director’s mandate, the employment agreement
or, as applicable, the consultancy agreement, and (ii) with respect to Selected Participants not qualifying as Executives or Directors,
within a period of one year as from the Date of Termination of the employment agreement or, as applicable, the consultancy agreement.

 

The Vested Stock Options that are not
exercised within the period referred to in the previous paragraph shall automatically lapse and become null and void. The Stock Options
that have not become Vested Stock Options at the Date of Termination of the director’s mandate, the employment agreement or, as
applicable, the consultancy agreement automatically lapse and become null and void.

 

Upon termination of a Selected Director’s
mandate for breach of his duties as a Director, a Selected Employee’s employment agreement for serious cause or, a Selected Consultant’s
consultancy agreement for breach of said agreement, all Stock Options shall, unless determined otherwise by the Board of Directors, whether
vested or not, automatically become definitely unexercisable as from the Date of Termination of the Director’s mandate, the employment
agreement or as applicable, the consultancy agreement.

 

    6/9

     

    

 

Free English translation — for information
purposes

 

		7.1.4	Consequences of legal retirement, disability or serious disease

 

In case the holder of a Stock Option
is a natural person, the following will apply: in the event of termination of the director’s mandate, the employment agreement,
or as applicable, the consultancy agreement of the Selected Participant as a consequence of legal retirement, disability or serious disease,
the (at that time) Vested Stock Options shall remain exercisable for the remaining term of the Stock Options pursuant to the terms and
conditions set forth in the Plan.

 

		7.2	Exercise Period

 

Vested Stock Options can only be exercised
during the following periods: during the term of the Stock Options, between March 1 and March 31 and between September 1 and September
30. Each Exercise Period shall close on the last banking day of the particular Exercise Period.

 

The Board of Directors may, however,
in its absolute discretion, provide for additional Exercise Periods and do so notably in case of a Take-Over (i.e. in case all Stock Options
automatically vest in accordance with 7.1.1 in fine above).

 

		7.3	Partial exercise

 

A Selected Participant may exercise
all or part of his/her Vested Stock Options. However, it is not possible to exercise a Stock Option with respect to fractions of Shares.

 

		7.4	Exercise procedure

 

A Stock Option shall be deemed to have
been exercised upon receipt by the Company, at the latest on the last banking day of the Exercise Period, of:

 

		(i)	A Notification signed by the Selected Participant and stating that a Stock Option or a specified number
of Stock Options is exercised.

 

		(ii)	Evidence of complete payment of the Exercise Price, within thirty (30) calendar days following the last
banking day of the Exercise Period in which the Stock Options were exercised, for the number of Shares as indicated in the Notification
provided sub (i), by bank transfer to a blocked account of the Company whose number is communicated by the Company.

 

		(iii)	In the event that a Stock Option is exercised by a person or persons other than the Selected Participant,
suitable proof of the right of this person or these persons to exercise the Stock Option.

 

		(iv)	Any and all statements and documents, which the Board of Directors deems desirable or necessary in order
to comply with all applicable legal and regulatory provisions, and the submission of which the Board of Directors consequently requests.

 

		7.5	Conditions for the issuance of Shares

 

		7.5.1	The Company shall only be obliged to issue the Shares as a result of
the exercise of the Stock Options, by registration in the Company’s share register or any other manner prescribed by the Belgian
Company Code, after all of the preceding conditions set forth in Article 7.4 have been fulfilled and following the completion of the capital
increase mentioned below.

 

		7.5.2	The Board of Directors, or two members thereof, shall, in accordance
with Article 591 of the Company Code (or any other provision having the same purport), have the capital increase, resulting from the exercise
of the Stock Options, and the fully paid in Shares thus subscribed for, acted before a notary public within 60 days after the closing
of the Exercise Period in which the Stock Options were exercised.

 

    7/9

     

    

 

Free English translation — for information
purposes

 

		7.5.3	If the Company is at that time listed on a regulated or public market,
the Company shall make application to the stock exchange in question for such Shares to be admitted for listing.

 

		7.5.4	The Company may at its discretion postpone the delivery of the Shares,
if this is necessary in order to comply with the applicable regulations or provisions of whatever nature, including but not limited to
public offer, registration and other obligations with respect to the Shares of the Company, as the Company deems appropriate.

 

Article
8 -CHANGE IN THE CAPITAL STRUCTURE OF THE COMPANY – EXERCISE OF THE STOCK OPTIONS BY VIRTUE OF LAW

 

		8.1	Change in the capital structure of the Company

 

Contrary to Article 501 of the Belgian
Company Code, the Company explicitly reserves the right to take all possible decisions and to enter into all possible transactions that
may have an impact on its capital, on the distribution of profits or on the distribution of liquidation proceeds or that may otherwise
affect the rights of the Selected Participants.

 

Should the rights of the Selected Participant
be affected by such decision or transaction, then the Selected Participant shall not be entitled to a change of the Exercise Price, a
change of the exercise conditions or any other form of (financial or other) compensation, unless such a decision or transaction would
have as its main purpose to prejudice the rights of the holders of the Stock Options.

 

In case of a merger, de-merger or stock
split of the Company, the rights of the outstanding Stock Options and/or Exercise Price of the Stock Options, shall be adapted in accordance
with the conversion ratios applied on the occasion of the merger, de-merger or stock split to the other shareholders.

 

		8.2	Exercise of the Stock Options by virtue of Law

 

If a Stock Option which is not exercisable
or which cannot be exercised pursuant to the issuance conditions (as determined in this Plan) becomes prematurely exercisable on the basis
of Article 501 of the Company Code and is also exercised pursuant to said Article, the Shares obtained by exercising the Stock Option
shall not be transferable, unless explicitly agreed upon by the Board of Directors, until the time the underlying Stock Options would
have become exercisable in accordance with the Plan.

 

Article
9 - MISCELLANEOUS

 

		9.1	Taxes and Social Security

 

The Company or a Subsidiary shall be
entitled, in accordance with the applicable law or practice, to withhold from any cash payment made to a Selected Participant, and/or
the Selected Participant shall be obliged to pay to the Company or to a Subsidiary (if requested for by the Company or a Subsidiary),
the amount of any tax and/or social security contributions, if any, attributable to or payable in connection with the grant, vesting or
exercise of any Stock Options or attributable to or payable in connection with the delivery of the Shares.

 

The Company or a Subsidiary shall also
be entitled, in accordance with the applicable law or practice, to make the necessary reporting, required as a result of the grant of
Stock Options, their vesting, their exercisability or the delivery of the Shares.

 

		9.2	Costs

 

Stamp duties and other similar duties
or taxes levied upon exercise of the Stock Options and/or the delivery of the new Shares shall be borne by the Selected Participant.

 

Costs related to the capital increase
that shall take place upon the exercise of the Stock Options shall be borne by the Company.

 

    8/9

     

    

 

Free English translation — for information
purposes

 

		9.3	Applicable law and Competent Courts

 

Belgian law governs the Plan. Disputes
shall fall under the exclusive jurisdiction of the Courts of Liège.

 

Stock Options subscribed to in the framework
of this Plan shall be governed by and construed in accordance with the Laws of Belgium.

 

		9.4	Notifications

 

Each Notification to a Selected Participant
shall be made to the address mentioned in the register of warrantholders. Each Notification to the Company, a Subsidiary or the Board
of Directors shall be validly made to the address of the registered office of the Company. Address changes must be communicated in accordance
with this provision.

 

		9.5	Relation to employment or consultancy agreement

 

Notwithstanding any provision of the
Plan, the rights and obligations of a Selected Participant as determined under the terms of his/her employment agreement, or as applicable,
consultancy agreement with the Company or any Subsidiary shall not be affected by his/her participation in the Plan or by any right that
he/she may have to participate therein. A Selected Participant who subscribes to Stock Options pursuant to the Plan shall have no rights
to compensation or damages in consequence of the termination of his/her employment agreement or, as applicable, consultancy agreement
with the Company or the Subsidiary for any reason whatsoever, insofar as those rights arise or may arise from the termination of the rights
which he/she would have or of the claims which he/she could make relating to the exercise of the Stock Options under the Plan as a result
of the termination of such employment agreement, or as applicable, consultancy agreement or from the loss or reduction in value of the
rights or advantages.

 

 

9/9Exhibit 10.7

 

AGREEMENT

 

BETWEEN

 

OncoMethylome Sciences, Inc., a company incorporated in the
state of Delaware and with offices in North Carolina. Hereinafter referred to as the COMPANY. The COMPANY is represented by Herman Spolders
for purposes of this Agreement.

 

And

 

Mr. Joseph Sollee, residing at                    .
Hereinafter referred to as EMPLOYEE.

 

Article
1 - Scope of Services

 

		1.1	The COMPANY hereby employs EMPLOYEE as General Counsel, and EMPLOYEE hereby accepts such employment upon the terms and conditions
set forth herein. EMPLOYEE shall report to the CEO (CEO being the CEO of OncoMethylome Sciences S.A. (the PARENT)). The tasks of EMPLOYEE
include but are not limited to the following:

 

		-	Coordinate the legal aspects of the Group

 

		-	Assist in the Group’s Corporate, Intellectual Property and Business Development activities

 

In the performance of those tasks EMPLOYEE shall not, without
the express prior written approval of the CEO, enter into any contract on behalf of the COMPANY or bind the COMPANY in any other way.

 

		1.2	While so employed, EMPLOYEE agrees to diligently and faithfully perform those tasks set forth in Section 1.1 and to use his
reasonable best efforts, skills and abilities to further the interests of the COMPANY. EMPLOYEE shall be based in the Raleigh-Durham area
of North Carolina, and shall conduct work on behalf of the COMPANY at the offices of the COMPANY in Durham, North Carolina or remotely,
on a schedule to be agreed from time to time between CEO and EMPLOYEE.

 

		1.3	EMPLOYEE agrees to comply with all applicable governmental laws, rules and regulations, and policies, standards and regulations
of the COMPANY now existing or hereafter promulgated

 

		1.4	EMPLOYEE confirms that he is in possession of all the necessary documents to be legally employed and to reside in the United
States.

 

     

     

    

 

Article
2 - Remuneration and Benefits

 

		2.1	EMPLOYEE shall receive an annual base salary of USD 200,000.00, less required federal and state withholdings and other authorized
deductions, payable in accordance with the COMPANY’S normal payroll schedule. If EMPLOYEE is employed for less than a full calendar
year, he will receive a pro-rata share of the annual base salary based on the time of actual service during the year.

 

Not later than June 30, 2008 or within thirty days after
the effective date of employment identified in Section 3.1, EMPLOYEE will be granted options to purchase 25,000 shares of common stock
of the PARENT, at an exercise price equal to the fair market value of the PARENT common stock at or near the date of grant. Such options
will be incentive stock options to the extent permissible under applicable tax laws. For clarity, (i) the above-referenced grant is in
addition to the existing options held by EMPLOYEE, which existing options shall continue to vest, each in accordance with its terms following
the effective date of employment, and (ii) based on EMPLOYEE’s prior and continuing service to the COMPANY, the one-year-of-service
cliff vesting limitation shall not be applicable to EMPLOYEE with respect to the above-referenced grant.

 

EMPLOYEE shall be eligible to participate in the COMPANY’s
group welfare and employee benefit plans made available generally to the COMPANY’s full-time employees, subject to and on a basis
consistent with the terms and conditions established by the applicable plan documents, with the cost of coverage under such plans to be
covered on the same basis as for other senior executives of COMPANY. EMPLOYEE shall be entitled annually to paid vacation and other paid
time off in compliance with all applicable laws and in accordance with the terms and conditions of the COMPANY’s vacation and professional
leave policies generally applicable to other senior executives of the COMPANY, as may be amended from time to time in the COMPANY’s
sole discretion. EMPLOYEE shall be:

 

 (i) eligible for annual bonuses to
be decided upon annually by the CEO and Board of Directors on the same basis as for other senior executives of COMPANY, with an initial
target annual bonus of 15%. The attribution of bonuses in any given year does not constitute an obligation for the COMPANY to attribute
such benefits in the ensuing years;

 

 (ii) eligible for employee stock options
(in addition to the above-specified hire options) to be decided upon annually by the CEO and Board of Directors. The attribution of stock
options in any given year does not constitute an obligation for the COMPANY to attribute such benefits in the ensuing years;

 

 (iii) entitled to 4 weeks of paid
holidays and vacation per calendar year. If EMPLOYEE starts his contract or terminates his contract other than on the last day of the
year, EMPLOYEE will be entitled to receive the pro-rata share of the 4 weeks mentioned in the previous sentence;

 

 (iv) eligible to participate in any
comprehensive group medical, dental and disability plans provided by COMPANY, to the extent allowed by the terms of such plans, with the
cost of coverage for EMPLOYEE (and, with respect to medical and dental plans, his family) to be covered by COMPANY; and

 

 (v) eligible to participate in any
401(k) plans provided by COMPANY, to the extent allowed by the terms of such plans.

 

		2.2	The COMPANY will reimburse EMPLOYEE for all reasonable expenses properly incurred by EMPLOYEE for the benefit of the COMPANY,
subject to the review and approval of the CEO, including for example telecommunications (i.e. blackberry) and legal licensure (U.S. State
Legal Bars and CLE programs). EMPLOYEE shall submit these expenses at the end of each month using the COMPANY’s Expense Reimbursement
Form and shall attach the original invoices to the Form.

 

    - 2 -

     

    

 

Article
3 - Term and Termination; Effect of Termination

 

		3.1	This contract will take effect on April 28, 2008 (or earlier at EMPLOYEE’s convenience) and shall continue until
EMPLOYEE’s employment is otherwise terminated, whether by EMPLOYEE or the COMPANY, each in its sole discretion. In connection with
any such termination, the COMPANY shall pay EMPLOYEE all compensation and benefits accrued, but unpaid (including any accrued but unused
vacation), up to the date of termination.

 

		3.2	All information, documents and material entrusted to EMPLOYEE within the framework of this Agreement shall remain the property
of the COMPANY. EMPLOYEE is required to return all such information, documents and material to the COMPANY (and all copies and reproductions
thereof) at the moment of termination of this Agreement for whatever reason.

 

		3.3	Except as otherwise provided below in this Section 3, if EMPLOYEE’s employment is terminated involuntarily by the COMPANY
without Cause, or EMPLOYEE resigns his employment for Good Reason, then: (i) the COMPANY shall continue to pay EMPLOYEE each month, for
a period of four (4) months from the date of termination, an amount equal to one twelfth (1/12) of EMPLOYEE’s annual base salary
in effect as of the date of termination, (ii) the COMPANY will maintain (and pay premiums on) EMPLOYEE’s group medical and dental
coverage during the period EMPLOYEE is receiving payments under clause (i) of this Section 3.3; and (iii) except in the case where EMPLOYEE
resigns based on a material diminution in his duties, responsibilities, authorities, powers or functions (i.e. clause (ii) of the Good
Reason definition), any outstanding but unvested or partially vested options held by EMPLOYEE in COMPANY and/or PARENT shall automatically
(or, to the extent required by the terms of the applicable Stock Option Plan, following necessary board action) become fully vested and
exercisable as of the effective date of such termination, with EMPLOYEE having a minimum of 90 days in which to exercise such option (or
longer, as provided in the applicable stock option plan or Stock Option Agreement and/or to account for any lock-up period or closed trading
window).

 

		3.4	In the event that any termination that triggers severance under Section 3.3(i) occurs because of a consolidation, merger, reorganization,
sale of all or substantially all of the assets or capital stock (including a control group tender offer) of COMPANY or PARENT, or other
business combination in which PARENT is not the surviving entity (a “Change of Control”), or in any event at any time within
a period commencing six months before and ending twelve months after a Change of Control, then PARENT (itself or through the COMPANY)
or the acquiring corporation, as the case may be, shall extend the severance period in Section 3.3(i) and benefits period in Section 3.300
from four (4) to six (6) months, at the same monthly rates; provided that if the PARENT or acquiring corporation offers a more favorable
general severance plan or program to similarly-situated executives of the COMPANY, EMPLOYEE may instead elect to participate in such plan
or program.

 

    - 3 -

     

    

 

		3.5	For purposes of this Article 3:

 

“Cause” means (i) any wanton or willful
dereliction of duties by EMPLOYEE, (ii) EMPLOYEE’s conviction of a felony involving moral turpitude, fraud, theft, embezzlement
or financial dishonesty that is materially detrimental to the COMPANY or its good will or that materially causes harm to COMPANY’S
relationships with its customers, suppliers or employees, (iii) EMPLOYEE’s habitual and intemperate use of alcohol or illegal drugs
that materially interferes with EMPLOYEE’s ability to perform the essential duties of his employment, or (iv) EMPLOYEE’s dishonest
or willful breach of the confidentiality, intellectual property or other material provisions of this Agreement provided however, that
COMPANY has provided EMPLOYEE with written notice thereof stating with specificity the facts and circumstances underlying the finding
of Cause and, if the basis for such finding of Cause is capable of being cured by EMPLOYEE, providing an opportunity to cure the same
within thirty (30) calendar days after receipt of such notice.

 

“Good Reason” means the occurrence of
any of the following without EMPLOYEE’s prior written consent: (i) a reduction in EMPLOYEE’s then current annual base salary,
(ii) a material diminution in EMPLOYEE’s duties, responsibilities, authorities, powers or functions (other than in connection with
EMPLOYEE’s termination by the COMPANY for Cause), (iii) a relocation of EMPLOYEE’s place of employment by more than fifty
(50) miles, (iv) a breach by the COMPANY of any material provision of this Agreement or of any equity award or agreement between EMPLOYEE
and PARENT, or (v) the failure of the COMPANY to obtain the assumption in writing of its obligations under this Agreement in all material
respects by any successor to all or substantially all of its assets after any Change of Control; provided however, that EMPLOYEE has provided
COMPANY (prior to his resignation) with written notice thereof stating with specificity the facts and circumstances underlying the finding
of Good Reason and, if the basis for such finding is capable of being cured by COMPANY, providing an opportunity to cure the same within
thirty (30) calendar days after receipt of such notice.

 

Article
4 - Confidentiality

 

		4.1	At all times, EMPLOYEE shall hold in strictest confidence and not use or disclose to any person, firm, corporation or any other
organisation or entity, including any representative or agent of the foregoing, without prior written authorisation of the COMPANY any
Confidential Information.

 

		4.2	“Confidential Information” shall mean, with respect to the COMPANY and its affiliates, any proprietary information,
technical data, trade secrets and know-how (including, without limitation, research, product plans, products, services, customer lists
and customers), markets, software, developments, inventions, processes, formulas, technology, designs, drawings, engineering, hardware
configuration information, marketing, finances, data, materials prepared for internal purposes and any other business information of the
COMPANY or its affiliates disclosed to EMPLOYEE either directly or indirectly in writing, orally or by drawings or observation. The Confidential
Information also includes all analyses, compilations, studies or other documents prepared by EMPLOYEE while in the employment of the COMPANY.
EMPLOYEE further understands that “Confidential Information” shall not include any of the foregoing items which has become
publicly known and made generally available through no wrongful act of EMPLOYEE or of others who were under confidentiality obligations
as to the item or items involved.

 

    - 4 -

     

    

 

		4.3	Notwithstanding the present provision, EMPLOYEE may use or disclose Confidential Information to the extent it can demonstrate,
by clear and convincing evidence that such Confidential Information:

 

 (i) at the time of disclosure to the
COMPANY is generally available to the public, or after such disclosure becomes generally available through no wrongful act by EMPLOYEE;

 

 (ii) is disclosed by EMPLOYEE in order
to comply with the requirements of applicable law or governmental regulations, provided that EMPLOYEE gives the COMPANY prior notice of
such disclosure and takes reasonable actions to avoid such disclosure or minimize its extent; or

 

 (iii) is independently developed
by EMPLOYEE without aid, application or use of the Confidential Information received from the COMPANY as far as related to the activities
of the COMPANY or the services it renders to the COMPANY.

 

		4.4	EMPLOYEE recognizes that the COMPANY and its affiliates have received and in the future will receive from third parties their
confidential or proprietary information subject to a duty on their part to maintain the confidentiality of such information and to use
it only for certain limited purposes. EMPLOYEE agrees to hold all such confidential or proprietary information in the strictest confidence
and not to disclose it to any person, firm, corporation or other organisation or to use it, except as necessary to carry out COMPANY business
and, where applicable, only as required or authorised under the terms of any agreement between the COMPANY or its affiliates and such
third party.

 

		4.5	All obligations of confidentiality under this Agreement shall terminate five (5) years from the date of the termination or
expiration of this Agreement, for any reason whatsoever.

 

Article
5 - Intellectual Property

 

		5.1	EMPLOYEE affirms its obligations to the COMPANY and its affiliates and agrees as follows, recognizing and expressly agreeing
that no additional consideration can be claimed for the assignment of the rights hereunder EMPLOYEE hereby irrevocably assigns, worldwide
and for the duration of the contract, all Intellectual Property to the COMPANY (or an affiliate or designee of the COMPANY as designated
by the COMPANY) (together with such person’s successors and assigns, the “Assignee”) who accepts, all of EMPLOYEES’s
rights in all Intellectual Property that it makes or conceives, whether as a sole inventor or sole author, or as a joint inventor or joint
author, whenever or wherever made or conceived in the course of EMPLOYEE’s employment with the COMPANY under the present agreement
provided and to the extent that such invention relates directly to the Field; to the maximum extent permitted by Section 66-57.1 of North
Carolina Commerce and Business Code, a copy of which is attached hereto as Exhibit A (the “Limited Exclusion Notification”).
This assignment shall not apply to Intellectual Property previously assigned to a former person or company; provided that such assignment
is in writing and precedes this assignment. EMPLOYEE understands and acknowledges that “Intellectual Property” shall
mean any information of a technical and/or business nature such as ideas, discoveries, inventions, trade secrets, know-how, software,
developments, inventions, processes, formulas, technology, designs, drawings, engineering, hardware configuration information and writings
or other works of authorship, as well as any texts, reports, images, logos, distinctive signs, slogans, schedules, databases, collections
of information, packaging, manuals, preparatory design material, inter alia for computer programs, translations, etc. (this enumeration
is non exhaustive) in each case made or conceived in the course of EMPLOYEE’s employment with the COMPANY under the present agreement
provided and to the extent related directly to the Field.

 

As far as copyrighted works are concerned, this assignment
is agreed upon by EMPLOYEE for all modes of exploitation known on the day of signature of the present agreement, in any form, two dimensional
or three-dimensional or in any other way, including in particular the right to record the work by all known means on every medium (paper,
three-dimensional or electronic), the right to make an unlimited number of copies of the work, the right to issue copies to the public,
the right to make the work public and to communicate the work to the public in any way (including via the Internet) and in all countries
of the world, the right to adapt and modify the work (additions, omissions, updates, ...), the right to translate the work in all languages
and the right to register the work as a trademark or as a design in the whole world . In case of exploitation of a copyrighted work which
enters within the scope of the present agreement in a way which was unknown at the date of signature of the present agreement, EMPLOYEE
agrees to negotiate with the COMPANY in good faith an assignment to the COMPANY of the right of exploitation unknown on the day of signature
of the present agreement, against a reasonable share in the profit of the exploitation of this work.

 

    - 5 -

     

    

 

In case moral rights exist to the work concerned, EMPLOYEE
expressly waives its right to be mentioned as the author in case of exploitation of the work, including computer programs and also expressly
waives its right to make the work public. It follows that only the COMPANY will decide unilaterally when and how the said work will be
communicated to the public. In case moral rights exist to the work concerned, EMPLOYEE grants the right to the COMPANY to make reasonable
modifications and adaptations to its work, in particular modifications inherent to translations, updating, modifications and adaptations
of computer programs and databases, modification of the layout of works (sites, databases, forms etc.), the making of summaries or, regarding
visual works, the enlargement, reduction, change of colours and contrasts, the isolation of individual elements etc., and EMPLOYEE expressly
waives his right to invoke its moral right in order to oppose these modifications or adaptations.

 

		5.2	EMPLOYEE agrees to abstain from using the Intellectual Property created in the Field by it as sole inventor or sole author
or joint inventor or joint author within the framework of the present agreement in violation of the rights assigned by the present agreement.

 

EMPLOYEE agrees in particular not to communicate the Intellectual
Property in the Field of which it is sole inventor or sole author or joint inventor or joint author to third parties without prior written
approval of the COMPANY.

 

		5.3	During and subsequent to EMPLOYEE’s employment with the COMPANY, upon the request and at the expense of the COMPANY or
its Assignee or its nominee and for no additional personal fees, EMPLOYEE agrees to execute any instrument that the COMPANY considers
necessary to secure for or maintain for the benefit of the COMPANY or its Assignee adequate patent and other property rights in any country
or jurisdiction with respect to any Intellectual Property. EMPLOYEE also agrees to assist the COMPANY or its Assignee as required to draft
said instruments and to obtain and enforce such rights. EMPLOYEE acknowledges and agrees that only the COMPANY or its Assignee shall have
the right to register a work, as described in Section 5.1, created by EMPLOYEE within the framework of the collaboration covered by the
present agreement, as a trademark or as a design.

 

		5.4	EMPLOYEE agrees to promptly disclose to the COMPANY or its Assignee any Intellectual Property when conceived or made by it,
in whole or in part, and to make and maintain adequate and current records thereof. Upon the termination of EMPLOYEE’s employment,
EMPLOYEE agrees to promptly turn over to the COMPANY or its Assignee all models, prototypes, drawings, records, documents and the like
in its possession or under its control, whether prepared by EMPLOYEE or others, relating to Intellectual Property, and any other work
done for the COMPANY and its affiliates related thereto. EMPLOYEE acknowledges that all such items are the sole property of the COMPANY
or its Assignee.

 

		5.5	Subject to Section 5.1, EMPLOYEE agrees that any patent application filed by EMPLOYEE claiming or covering Intellectual Property
in the Field within 6 months following termination of his employment with the COMPANY shall be the sole property of the COMPANY or its
Assignee, unless and until finally determined by a court of competent jurisdiction to have been made and conceived after the termination
of its collaboration with the COMPANY or its Assignee.

 

Article
6 - Non-Compete and Other Activities

 

		6.1	EMPLOYEE undertakes, during the execution of this Agreement and, in case of termination of this Agreement, either by it, voluntarily,
or by the COMPANY, for a period of six months thereafter anywhere within the prohibited area, to the COMPANY, (i) not to exercise operational
activities, as an employee, officer or in any other manner of another company that would compete with the activities of the COMPANY in
the field of genomic and genetic based clinical diagnostic cancer services (the “Field”), (ii) not to solicit, entice
away (or try to do so) any clients or customers or prospective clients or customers of the COMPANY, anywhere in the world and (iii) not
to be involved, directly or indirectly, in whatever capacity, in activities which are competing with the activities of the COMPANY in
the Field. For the purpose of this provision, “prohibited area” includes each and all of the following geographic areas: (i)
within 50 miles of Durham, North Carolina, (ii) North Carolina, (iii) North America, and (iv) Europe. With respect to this provision,
EMPLOYEE acknowledges that the COMPANY competes in a global market and that unfair competition can only be prevented by enforcing this
specific provision in the prohibited locations specifically set forth in this Article.

 

		6.2	Subject to the non-compete provisions of Section 6.1 and the fulfillment of EMPLOYEE’s primary duties to the COMPANY
in accordance with Article 1, EMPLOYEE may engage in independent commercial, legal and/or business activities so long as such activities
do not, in the reasonable opinion of the CEO, conflict with the activities of COMPANY or the proper performance of EMPLOYEE’s duties
and responsibilities to the COMPANY. EMPLOYEE will keep the CEO informed of the nature of such outside activities as appropriate.

 

    - 6 -

     

    

 

Article
7 - Miscellaneous

 

		7.1	EMPLOYEE acknowledges and agrees that the foregoing covenants and provisions of this Agreement are reasonably necessary for
the protection of the COMPANY and that such covenants and provisions are reasonably limited with respect to the activities prohibited,
the duration thereof, the geographical area thereof, the scope thereof and the effect on EMPLOYEE and the general public. EMPLOYEE further
acknowledges and agrees that the purpose and effect of such restrictive covenants and provisions is solely to protect the COMPANY for
a limited period of time from unfair competition by EMPLOYEE, and that the promises and benefits contained in this Agreement are conditioned
upon EMPLOYEE agreeing to abide by and be bound by all of the covenants and provisions contained in this Agreement.

 

		7.2	Any litigation under this Agreement may be brought by the COMPANY in the State of North Carolina, notwithstanding that EMPLOYEE
is not at that time a resident of the State of North Carolina and cannot be served process within that state. EMPLOYEE hereby irrevocably
consents to the jurisdiction of the courts of North Carolina (whether federal or state courts) over his or her person.

 

		7.3	EMPLOYEE represents that he has not been debarred nor received notice of any action or threat with respect to his debarment
under the provisions of the Generic Drug Enforcement Act of 1992, 21 U.S.C. § 335 (a). EMPLOYEE agrees promptly to notify COMPANY
upon receipt of any such notice and further agree, upon COMPANY’S request, to provide a separate written certification, on a form
provided by COMPANY, to this effect.

 

		7.4	EMPLOYEE agrees that this Agreement supersedes any agreement or understanding previously existing between the COMPANY and its
affiliates (including their predecessors) and EMPLOYEE relating to the matters contained herein.

 

		7.5	EMPLOYEE agrees that this instrument is the whole agreement between the COMPANY and EMPLOYEE and that no modification or variation
shall be deemed valid unless provided for in a subsequent written agreement signed by both Parties.

 

		7.6	EMPLOYEE’s employment with the COMPANY is not for a specific term and can be terminated by EMPLOYEE or the COMPANY at
any time for any reason, with or without cause. EMPLOYEE acknowledges and agrees that any contrary representations which may have been
made or which may be made to EMPLOYEE were not authorized by the COMPANY and are superseded by this agreement. The COMPANY request that
all of its employees, to the extent possible, give advance notice if they intend to resign.

 

    - 7 -

     

    

 

		7.7	The following provisions shall survive expiration or termination of this Agreement for any reason: Section 6.1 and Articles
3, 4, 5 and 7; each in accordance with its terms. Expiration or termination of this Agreement for any reason shall not (i) relieve the
parties of any liability or obligation which accrued hereunder prior to the effective date of such termination or expiration, (ii) preclude
either party from pursuing all rights and remedies it may have hereunder or at law or in equity, with respect to any breach of this Agreement
or (iii) prejudice either party’s right to obtain performance of any obligation.

 

		7.8	In the event EMPLOYEE leaves the employment of the COMPANY for any reason, EMPLOYEE agrees that the COMPANY is entitled to
communicate EMPLOYEE’s continuing obligations under this Agreement to any future or potential employer and EMPLOYEE hereby consents
to any such communication or notification.

 

		7.9	If any part of any covenant or provision contained in this Agreement is determined by a court of competent jurisdiction, or
by any arbitration panel to which a dispute is submitted, to be invalid, illegal or incapable of being enforced, then the court or arbitration
panel so deciding shall interpret such provisions in a manner so as to enforce them to the fullest extent of the law. The provisions of
this Agreement shall be deemed severable, and the invalidity or unenforceability of any other provisions (or part thereof) of this Agreement
shall in no way affect the validity or enforceability of any other provisions (or remaining part thereof).

 

		7.10	By signing this Agreement, EMPLOYEE represents and warrants that EMPLOYEE is not under any obligation to any person or other
third party and does not have any other interest that is inconsistent or in conflict with this Agreement, or that would prevent, limit
or impair its performance of any of the covenants hereunder or its duties as an EMPLOYEE of the COMPANY.

 

		7.11	Except as otherwise provided herein, no failure or delay of a Party to exercise any right or remedy under this Agreement shall
be considered as a waiver of such right or remedy, or any other right and remedy under this Agreement. EMPLOYEE agrees that all remedies
available to the COMPANY by reason of a breach of any of the foregoing provisions of this Agreement are cumulative and that none is exclusive
and that all remedies may be exercised concurrently or consecutively at the option of the COMPANY.

 

		7.12	This Agreement shall bind and inure to the benefit of the parties and their respective successors and permitted assigns. The
COMPANY may assign this Agreement to a wholly-owned subsidiary, “spin-off’ COMPANY, or other entity affiliated with the COMPANY.
EMPLOYEE shall not assign his rights or obligations hereunder to any person or entity without the prior written consent of the COMPANY.

 

		7.13	If a benefit promised herein is otherwise provided by the terms of a plan or policy sponsored by the COMPANY on account of
the same event giving rise to the benefit under this Agreement, nothing herein shall be construed to entitle EMPLOYEE to duplicate benefits.

 

I HAVE READ THIS AGREEMENT CAREFULLY AND I UNDERSTAND AND ACCEPT THE
OBLIGATIONS WHICH IT IMPOSES UPON ME WITHOUT RESERVATION. I SIGN THIS AGREEMENT VOLUNTARILY AND FREELY, IN DUPLICATE, WITH THE UNDERSTANDING
THAT ONE COUNTERPART WILL BE RETAINED BY THE COMPANY AND THE OTHER COUNTERPART WILL BE RETAINED BY ME.

  

	/s/ Joseph Sollee	 	April 14, 2008	 	/s/ Herman Spolders	 	April 14, 2008
	 	 	 	 	 	 	 
	EMPLOYEE signature & date	 	 	 	 	 	COMPANY signature & date

 

    - 8 -

     

    

 

EXHIBIT A

 

LIMITED EXCLUSION NOTIFICATION

 

δ 66-57.1 Employee’s right to certain inventions

 

Any provision in an employment
agreement which provides that the employees shall assign or offer to assign any of his rights in an invention to his employer shall not
apply to an invention that the employee developed entirely on his own time without using the employer’s equipment, supplies, facility
or trade secret information except for those inventions that (i) relate to the employer’s business or actual or demonstrably anticipated
research and development, or (ii) result from any work performed by the employee for the employer. To the extent a provision in an employment
agreement purports to apply to the type of invention described, it is against the public policy of this State and is unenforceable. The
employee shall bear the burden of proof in establishing that his invention qualifies under this section.

 

	 	ACKNOWLEDGMENT OF RECEIPT:
	 	 
	 	/s/ Joseph Sollee
	 	 
	 	Employee’s Signature
	 	 
	 	Dated: April 14, 2008

 

    - 9 -

     

    

 

	 	 

                            

                           Jan Groen

President & CEO

+1 949 812 6979 x101

jan.groen@mdxhealth.com

 

January 27, 2014

 

VIA EMAIL ONLY

 

Joseph Sollee

117 Faison Road

Chapel Hill, NC 27517

 

		Re:	Amendment to Employment Agreement

 

Dear Joe:

 

This letter sets forth the terms of our proposal, in connection with
your (new) position as “Executive Vice President of Corporate Development, General Counsel and Secretary”, to amend certain
provisions of your Employment Agreement with MDxHealth, Inc. (formerly known as Oncomethylome Sciences, Inc.), which agreement initially
took effect on April 28, 2008 (the “Agreement”). Specifically, the parties have agreed, as and from the date of this letter,
to:

 

		A.	Expand the four (4) months severance period set forth in Section 3.3(i) of the Agreement to nine (9) months. As such, Section 3.4
of the Agreement shall have no more effect and is hereby deleted in its entirety; and

 

		B.	Add a new Section 7.14 to the Agreement, as set forth on Schedule I enclosed with this letter.

 

If the foregoing properly and accurately reflects your understanding
of our agreement, please execute in the space provided below and return the original executed copy to me for my records. Except as expressly
amended by this letter, the Agreement shall remain in full force and effect

 

	 	Sincerely,
	 	 
	 	Jan Groen, on behalf of MDxHealth, Inc.
	 	 
	 	/s/ Jan Groen
	 	J. Groen
	 	CEO

 

	 	WITNESSED BY:
	 	 
	 	 	/s/ Christopher Thibodeau
	 	Name: 	Christopher Thibodeau
	 	Title:
	 	Date: February 1, 2014

 

	ACKNOWLEDGED & AGREED:	 
	 	 
	By:	/s/ Joseph Sollee	 
	 	Joseph Sollee	 
	 	 
	 	Date:February 1, 2014	 

 

15279 Alton Parkway | Suite 100 | Irvine,
CA 92618 | 949.812.6979 | Fax: 949.242.2960 | www.mdxhealth.com

 

    - 10 -

     

    

 

Schedule I

 

		7.14	The intent of the parties is that payments and benefits under this Agreement are either exempt from or comply with Section
409A of the U.S. Internal Revenue Code (“Section 409A”) and this Agreement shall be interpreted to that end. The parties acknowledge
and agree that the interpretation of Section 409A and its application is uncertain and may be subject to change as additional guidance
and interpretations become available. If any payments or other benefits due to EMPLOYEE could cause the application of an accelerated
or additional tax under Section 409A, such payments or other benefits shall be deferred or restructured, to the extent possible (without
any reduction in such payments or benefits ultimately paid or provided to EMPLOYEE), in a manner that does not cause such an accelerated
or additional tax. The Company shall consult with EMPLOYEE in good faith regarding the implementation of the provisions of this Section
7.14. In this regard:

 

 (i) Six-Month Delay for Specified
Employees. If any payment, compensation or other benefit provided to the EMPLOYEE in connection with his employment termination is
determined, in whole or in part, to constitute “nonqualified deferred compensation” within the meaning of Section 409A and
the EMPLOYEE is a “specified employee” as defined in Section 409A, no part of such payments shall be paid before the day that
is six (6) months plus one (1) day after the EMPLOYEE’s date of termination or, if earlier, the EMPLOYEE’s death (the “New
Payment Date”). The aggregate of any payments that otherwise would have been paid to the EMPLOYEE during the period between the
date of termination and the New Payment Date shall be paid to the EMPLOYEE in a lump sum on such New Payment Date. Thereafter, any payments
that remain outstanding as of the day immediately following the New Payment Date shall be paid without delay over the time period originally
scheduled, in accordance with the terms of this Agreement.

 

(ii) Termination as a Separation
from Service. A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing
for the payment of any amounts or benefits subject to Section 409A upon or following a termination of employment until such termination
is also a “separation from service” within the meaning of Section 409A and for purposes of any such provision of this Agreement,
references to a “resignation,” “termination,” “terminate,” “termination of employment”
or like terms shall mean separation from service.

 

(iii) Payments for Reimbursements
and In-Kind Benefits. All reimbursements for costs and expenses under this Agreement shall be paid in no event later than the end
of the calendar year following the calendar year in which the EMPLOYEE incurs such expense. With regard to any provision herein that provides
for reimbursement of costs and expenses or in-kind benefits, except as permitted by Section 409A, (a) the right to reimbursement or in-kind
benefits shall not be subject to liquidation or exchange for another benefit, and (b) the amount of expenses eligible for reimbursements
or in-kind benefits provided during any taxable year shall not affect the expenses eligible for reimbursement or in-kind benefits to be
provided in any other taxable year.

 

(iv) Payments within Specified
Number of Days. Whenever a payment under this Agreement specifies a payment period with reference to a number of days, the actual
date of payment shall be within the sole discretion of the COMPANY.

 

(v) Installments as Separate Payment.
If under this Agreement, an amount is paid in two (2) or more installments, for purposes of Section 409A, each installment shall be treated
as a separate payment.

 

 

- 11 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}]]